BridgeBio Pharma, Inc. (BBIO)

25.90 +0.94 (+3.77%) At close: 04:00PM EDT

BridgeBio Pharma, Inc.

3160 Porter Drive
Suite 250
Palo Alto, CA 94304
United States
650 391 9740
https://bridgebio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 550

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Neil Kumar Ph.D.	Co-Founder, CEO & Director	1.53M	N/A	1979
Dr. Charles J. Homcy M.D.	Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director	563.2k	N/A	1948
Dr. Frank P. McCormick Ph.D.	Co-Founder, Chairman of Oncology & Director	542.78k	N/A	1950
Dr. Brian C. Stephenson C.F.A., Ph.D.	CFO & Secretary	1.15M	N/A	1981
Dr. Richard H. Scheller Ph.D.	Chairman of Research & Development	509.62k	N/A	1953
Dr. Thomas Trimarchi Ph.D.	President & COO	N/A	N/A	N/A
Dr. Uma Sinha Ph.D.	Chief Scientific Officer	1.31M	N/A	1958
Grace Rauh	Vice President of Communications	N/A	N/A	N/A
Mr. Eli M. Wallace Ph.D.	Chief Scientific Officer of Oncology	N/A	N/A	1967
Dr. Eric Michael David J.D., M.D., Ph.D.	Chief Executive Officer of Gene Therapy	N/A	N/A	1972

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Corporate governance

BridgeBio Pharma, Inc.’s ISS governance QualityScore as of 1 October 2024 is 8. The pillar scores are Audit: 2; Board: 9; Shareholder rights: 9; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.